Poly(ADP-ribosyl)ation in asthma and other lung diseases

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Inhibition of poly(ADP-ribosyl)ation in oxidative stress-related pathologies has recently emerged as a very effective anti-inflammatory intervention in animal models of arthritis, colitis, diabetes and shock. Recent data from three laboratories also support the role of poly(ADP-ribose) polymerase-1 (PARP-1) activation in asthma. Similarly to other inflammatory conditions, the protective effects of PARP inhibition and the PARP-1 knock out phenotype in asthma models have been attributed to inhibition of inflammatory signal transduction (mainly via NF-κB) and of oxidative stress-induced cell dysfunction and tissue injury. Here I discuss the complex role of poly(ADP-ribosyl)ation in the regulation of inflammatory cell migration, chemokine and cytokine production and expression of other inflammatory mediators (inducible nitric oxide synthase, matrix metalloproteinases) in asthma. The role of PARP-1 in other oxidative stress-related lung diseases such as asbestosis, silicosis, acute respiratory distress syndrome and ischemia-reperfusion injury is also reviewed.

Original languageEnglish
Pages (from-to)83-92
Number of pages10
JournalPharmacological Research
Volume52
Issue number1 SPEC. ISS.
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Adenosine Diphosphate
Lung Diseases
Oxidative Stress
Asthma
Asbestosis
Silicosis
Adult Respiratory Distress Syndrome
Nitric Oxide Synthase Type II
Colitis
Reperfusion Injury
Matrix Metalloproteinases
Chemokines
Arthritis
Cell Movement
Shock
Signal Transduction
Anti-Inflammatory Agents
Animal Models
Pathology
Cytokines

Keywords

  • Acute respiratory distress syndrome
  • Allergy
  • Asbestosis
  • Asthma
  • Chemokines
  • Cytokines
  • Inflammation
  • Oxidative stress
  • Peroxynitrite
  • Poly(ADP-ribose) polymerase
  • Silicosis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Poly(ADP-ribosyl)ation in asthma and other lung diseases. / Virag, L.

In: Pharmacological Research, Vol. 52, No. 1 SPEC. ISS., 07.2005, p. 83-92.

Research output: Contribution to journalArticle

@article{fb02ca1c38164e41b86c58d5ff66eb67,
title = "Poly(ADP-ribosyl)ation in asthma and other lung diseases",
abstract = "Inhibition of poly(ADP-ribosyl)ation in oxidative stress-related pathologies has recently emerged as a very effective anti-inflammatory intervention in animal models of arthritis, colitis, diabetes and shock. Recent data from three laboratories also support the role of poly(ADP-ribose) polymerase-1 (PARP-1) activation in asthma. Similarly to other inflammatory conditions, the protective effects of PARP inhibition and the PARP-1 knock out phenotype in asthma models have been attributed to inhibition of inflammatory signal transduction (mainly via NF-κB) and of oxidative stress-induced cell dysfunction and tissue injury. Here I discuss the complex role of poly(ADP-ribosyl)ation in the regulation of inflammatory cell migration, chemokine and cytokine production and expression of other inflammatory mediators (inducible nitric oxide synthase, matrix metalloproteinases) in asthma. The role of PARP-1 in other oxidative stress-related lung diseases such as asbestosis, silicosis, acute respiratory distress syndrome and ischemia-reperfusion injury is also reviewed.",
keywords = "Acute respiratory distress syndrome, Allergy, Asbestosis, Asthma, Chemokines, Cytokines, Inflammation, Oxidative stress, Peroxynitrite, Poly(ADP-ribose) polymerase, Silicosis",
author = "L. Virag",
year = "2005",
month = "7",
doi = "10.1016/j.phrs.2005.02.012",
language = "English",
volume = "52",
pages = "83--92",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "1 SPEC. ISS.",

}

TY - JOUR

T1 - Poly(ADP-ribosyl)ation in asthma and other lung diseases

AU - Virag, L.

PY - 2005/7

Y1 - 2005/7

N2 - Inhibition of poly(ADP-ribosyl)ation in oxidative stress-related pathologies has recently emerged as a very effective anti-inflammatory intervention in animal models of arthritis, colitis, diabetes and shock. Recent data from three laboratories also support the role of poly(ADP-ribose) polymerase-1 (PARP-1) activation in asthma. Similarly to other inflammatory conditions, the protective effects of PARP inhibition and the PARP-1 knock out phenotype in asthma models have been attributed to inhibition of inflammatory signal transduction (mainly via NF-κB) and of oxidative stress-induced cell dysfunction and tissue injury. Here I discuss the complex role of poly(ADP-ribosyl)ation in the regulation of inflammatory cell migration, chemokine and cytokine production and expression of other inflammatory mediators (inducible nitric oxide synthase, matrix metalloproteinases) in asthma. The role of PARP-1 in other oxidative stress-related lung diseases such as asbestosis, silicosis, acute respiratory distress syndrome and ischemia-reperfusion injury is also reviewed.

AB - Inhibition of poly(ADP-ribosyl)ation in oxidative stress-related pathologies has recently emerged as a very effective anti-inflammatory intervention in animal models of arthritis, colitis, diabetes and shock. Recent data from three laboratories also support the role of poly(ADP-ribose) polymerase-1 (PARP-1) activation in asthma. Similarly to other inflammatory conditions, the protective effects of PARP inhibition and the PARP-1 knock out phenotype in asthma models have been attributed to inhibition of inflammatory signal transduction (mainly via NF-κB) and of oxidative stress-induced cell dysfunction and tissue injury. Here I discuss the complex role of poly(ADP-ribosyl)ation in the regulation of inflammatory cell migration, chemokine and cytokine production and expression of other inflammatory mediators (inducible nitric oxide synthase, matrix metalloproteinases) in asthma. The role of PARP-1 in other oxidative stress-related lung diseases such as asbestosis, silicosis, acute respiratory distress syndrome and ischemia-reperfusion injury is also reviewed.

KW - Acute respiratory distress syndrome

KW - Allergy

KW - Asbestosis

KW - Asthma

KW - Chemokines

KW - Cytokines

KW - Inflammation

KW - Oxidative stress

KW - Peroxynitrite

KW - Poly(ADP-ribose) polymerase

KW - Silicosis

UR - http://www.scopus.com/inward/record.url?scp=19444369704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444369704&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2005.02.012

DO - 10.1016/j.phrs.2005.02.012

M3 - Article

C2 - 15911336

AN - SCOPUS:19444369704

VL - 52

SP - 83

EP - 92

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 1 SPEC. ISS.

ER -